Can the FMR1 (Fragile X) gene serve as predictor of response to ovarian stimulation?

Reproductive Sciences

Volumn 16, Issue 5, 2009, Pages 462-467

  Gleicher, Norbert ^a,b,f   Weghofer, Andrea ^a,c   Oktay, Kutluk ^a,d   Barad, David H ^a,e  

^a Foundation for Reproductive Medicine   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f CENTER FOR HUMAN REPRODUCTION   (United States)

Author keywords

FMR1 gene; Fragile X; Gonadotropins; Ovarian aging; Ovarian resistance; Ovarian stimulation.; Premarure ovarian senescence

Indexed keywords

GONADOTROPIN; MUELLERIAN INHIBITING FACTOR;

ADULT; ARTICLE; FEMALE; FEMALE FERTILITY; FERTILIZATION IN VITRO; FMR1 GENE; GENE; HORMONAL REGULATION; HUMAN; MAJOR CLINICAL STUDY; OOCYTE; OVARY; OVULATION INDUCTION; PRIORITY JOURNAL; TRINUCLEOTIDE REPEAT;

ADULT; FEMALE; FERTILIZATION IN VITRO; FRAGILE X MENTAL RETARDATION PROTEIN; HUMANS; INFERTILITY, FEMALE; OOCYTE RETRIEVAL; OVULATION INDUCTION; PREDICTIVE VALUE OF TESTS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 64749102263     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719108328617     Document Type: Article

References (24)

1. Wittenberger MD, Hagerman RJ, Sherman SL, et al. The FMR1 premutation and reproduction. Fertil Steril. 2007 ; 87: 456-465.
2. Murray A., Ennis S., Mac Swiney F., Webb J., Morton NE Reproductive and menstrual history of females with fragile X expansions. Eur J Hum Genetics. 2000 ; 8: 247-252.
3. Bretherick KL, Fluker MR, Robinson WP FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet. 2005 ; 117: 376-382.
4. Bodega B., Bione S., Dalprà L., et al. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod. 2007 ; 21952-21957.
5. Welt CK, Smith PC, Taylor AE Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endo Metab. 2004 ; 89: 4569-4574.
6. Gleicher N., Weghofer A., Barad DH A pilot study on premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone. Fertil Steril. 2008 ; doi:10.1016/ j.fertnstert.2008.01.098.
7. Gleicher N., Weghofer A., Barad DH A pilot study of premature ovarian senescence: II. Different genotype and phenoptype for genetic and autoimmune etiologies. Fertil Steril. 2008 ; doi:10. 1016/j.fertnstert.2008.01.099.
8. Gleicher N., Weghofer A., Oktay K., Barad DH Can the FMR1 (fragile X) gene also serve as an infertility test? Submitted for publication; or Triple CGG expansions on the FMR1 gene and response to ovarian stimulation. Fertil Steril 2008 ; 64th Annual Meeting of ASRM, San Francisco, CA, November 8-12, 2008 ; P375.
9. Fu YH, Kuhl DP, Pizzuti A., et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell. 1991 ; 67: 1047-1058.
10. Chen LS, Tassone F., Sahota P., Hagermann PJ The (CGG)n repeat element within the 5'untranslated region of the FMR1 message provides both positive and negative cis effects on in vivo translation of a downstream reporter. Hum Mol Genet. 2003 ; 12: 3067-3074.
11. Nikolaou D., Templeton A. Early ovarian ageing: a hypothesis. Detection and clinical relevance. Hum Reprod. 2003 ; 18: 1137-1139.
12. Koh HS, van Asselt KM, van der Schouw YT, Grobbee DE, teVelde ER, Pearson PL, Peeters PH Subfertility reflects accelerated ovarian ageing. Hum Reprod. 2003 ; 18: 644-648.
13. Barad D., Weghofer A., Gleicher N. Age-specific levels for basal follicle-stimulating hormone assessment of ovarian function. Obstet Gynecol. 2007 ; 109: 1404-1410.
14. ACOG committee opinion. No.338: Screening for fragile X syndrome. Obstet Gynecol. 2006 ; 107: 1483-1485.
15. Siristatidis CS, Hamilton MP What should be the maximum FSH dose in IVF/ICSI in poor responders ? J Obstet Gynaecol. 2007 ; 27: 401-405.
16. Rombauts L. Is there a recommended maximum starting dose of FSH in IVF ? J Assist Reprod Genet. 2007 ; 24: 343-349.
17. Out HJ, Thomas LE Optimizing the gonadotropin dose regimen. Int Surg. 2007 ; 91 (suppl 5). S15 - S24.
18. Gleicher N., Weghofer A., Barad DH Age-specific ovarian function testing: a concept whose time has come. Expert Rev Obstet Gynecol 2008 ; 3: 595-600.
19. Tsigkou A., Marzotti S., Borges L., et al. High serum inhibin concentration discriminates autoimmune oophoritis from other forms of primary ovarian insufficiency. J Clin Endocrin Metab. 2008 ;doi:10.1210/jc.2007-1675.
20. Burger NZ, Johnson JV Androgen production in women. In: Tulandi T, Gelfand MM, eds. Androgens and Reproductive Aging. London and New York: Taylor & Francis; 2006: 1-4.
21. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod. 2000 ; 15: 2129-2132.
22. Barad D., Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril. 2005 ; 84: 756.
23. Barad D., Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod. 2006 ; 21: 2845-2849.
24. Barad D., Brill H., Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet. 2007 ; 24: 629-634.